Revolutionizing CNS Cancer Diagnostics

Welcome to CNSide™

(pronounced see • inside)

Discover advanced diagnostic solutions that provide powerful insights for patients with Leptomeningeal Metastases (LM).

About CNSide™

CNSide Diagnostics, LLC is a company dedicated to developing and commercializing proprietary clinical diagnostic laboratory assays. The first-in-class CNSide™ CSF assay is performed in a CLIA-registered facility in Houston, Texas at the request of top cancer physicians in the U.S.

CNSide™ is a highly sensitive, cerebrospinal fluid-based, laboratory developed test (LDT) for patients with Leptomeningeal Metastases (LM) from carcinomas and melanomas. By enabling quantitative analysis and molecular characterization of tumor cells, we provide powerful insights to healthcare providers that guide patient care and treatment decisions.

Our Mission and Vision

At CNSide Diagnostics, LLC, our mission is to revolutionize the clinical management of patients with Leptomeningeal Metastases (LM) through innovative diagnostic solutions.

Our vision is to improve patient outcomes by delivering cutting-edge diagnostics that enable personalized and effective treatment strategies.



What Physician Experts Say

“The FORESEE trial met its key primary and secondary endpoints, objectively showing that CNSide™ has very high clinical utility for treating physicians. CNSide is a more sensitive and definitive test for LM and has the potential to permit earlier diagnosis, manage our patients with more diagnostic precision, and hopefully improve therapeutic outcomes for our patients with LM.”